他汀用于1型糖尿病成人一级预防的安全性与有效性:目标试验模拟
本研究利用英国初级保健数据,对25-84岁、基线LDL-C≥2.6 mmol/L或非HDL-C≥3.4 mmol/L的1型糖尿病成人进行序贯目标试验模拟,比较启动他汀与不启动的结局。纳入4,176例启动者和16,704例非启动者,中位随访6年。他汀与全因死亡和主要心血管事件风险降低相关,不良反应风险很低,女性、≥40岁、LDL-C≥3.4 mmol/L及预测心血管风险较高者绝对风险降低更明显。
要点
- 1型糖尿病成人启动他汀与全因死亡和主要心血管事件风险降低相关。
- 他汀相关肌病风险未见增加,肝功能障碍风险信号较弱。
- 女性、≥40岁、LDL-C≥3.4 mmol/L者绝对风险降低更明显。
核心结论
- 在1型糖尿病成人中,启动他汀进行一级预防与全因死亡和主要心血管事件风险降低相关,不良反应风险很低。
研究设计与样本
- 采用英国IQVIA医学研究数据数据库进行序贯目标试验模拟,比较启动他汀与不启动他汀。
- 纳入25至84岁、有1型糖尿病诊断记录且使用胰岛素、基线LDL-C≥2.6 mmol/L或非HDL-C≥3.4 mmol/L者。
- 排除已有冠心病、心肌梗死、卒中、心力衰竭、肌病、肝病、风湿性心脏病、精神分裂症或癌症者。
- 共纳入4,176例他汀启动者和16,704例非启动者,中位随访6年。
主要发现
- 与不启动他汀相比,全因死亡绝对风险差(ITT)为-1.66%(95%CI:-2.79%至-0.45%),PP为-3.48%(95%CI:-4.68%至-2.07%)。
- 主要心血管事件绝对风险差(ITT)为-1.63%(95%CI:-2.57%至-0.53%),PP为-2.69%(95%CI:-4.00%至-1.22%)。
- 部分分析提示肝功能障碍风险略有增加,但肌病无关联。
- 亚组分析中,女性、≥40岁、基线LDL-C≥3.4 mmol/L及预测心血管风险较高者绝对风险降低通常更大。
临床怎么用
- 对于1型糖尿病成人一级预防,可考虑启动他汀以降低全因死亡和主要心血管事件风险。
- 个体化决策时可参考女性、≥40岁、LDL-C≥3.4 mmol/L及预测心血管风险较高者绝对获益更大的特点。
局限性
- 本研究为观察性目标试验模拟,非随机对照试验,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no consensus for using statins for primary prevention of cardiovascular disease (CVD) and all-cause mortality in adults with type 1 diabetes mellitus (T1DM), because no randomized controlled trial has exclusively investigated statins in this population. OBJECTIVES: In this study, the authors sought to evaluate the long-term risks and benefits of statins for primary prevention in adults with T1DM. METHODS: We performed a sequential target trial emulation comparing statin initiation vs noninitiation using UK primary care data from the IQVIA Medical Research Data database. Persons aged 25 to 84 years with a diagnosis record of T1DM with prescription of insulin from January 2005 to December 2016 were included if they had baseline low-density lipoprotein-cholesterol (LDL-C) ≥2.6 mmol/L (100 mg/dL) or non-high-density lipoprotein cholesterol ≥3.4 mmol/L (130 mg/dL). Persons with preexisting coronary artery disease, myocardial infarction, stroke, heart failure, myopathy, liver disease, rheumatic heart disease, schizophrenia or cancer were excluded. Main outcome measures were all-cause mortality, major CVD and adverse events (myopathy and liver dysfunction). We estimated 10-year absolute risk differences (RDs) for the observational analogues of the intention-to-treat (ITT) and per-protocol (PP) effects. RESULTS: We included 4,176 statin initiator (mean age of 45 years, 33.1% <40 years, 40.6% female) and 16,704 noninitiator person-trials with median follow-up of 6 years. Compared with noninitiation, statins were associated with reductions in all-cause mortality (RDITT: -1.66% [95% CI: -2.79% to -0.45%]; RDPP: -3.48% [95% CI: -4.68% to -2.07%]) and major CVD (RDITT: -1.63% [95% CI: -2.57% to -0.53%]; RDPP: -2.69% [95% CI: -4.00% to -1.22%]). Some analyses suggested a slight association with increased risk of liver dysfunction but no association with myopathy. In subgroup analyses, absolute risk reductions were generally larger in women, persons ≥40 years of age, persons with baseline LDL-C ≥3.4 mmol/L (130 mg/dL), and persons with a higher predicted cardiovascular risk. CONCLUSIONS: Among adults with T1DM, statin initiation for primary prevention was associated with reductions in all-cause mortality and major CVD with a very low risk of adverse effects. The differences in absolute risk reductions can help guide personalized statin treatment decisions in T1DM.
引用
- Blais JE, Yan VKC, Chan EWY, et al. Safety and Effectiveness of Statins for Primary Prevention in Adults With Type 1 Diabetes: An Emulation. J Am Coll Cardiol. 2025. PMID: 40930617. doi:10.1016/j.jacc.2025.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。